Metastatic Solid Tumor
122
52
70
13
Key Insights
Highlights
Success Rate
41% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
15.6%
19 terminated out of 122 trials
40.6%
-45.9% vs benchmark
0%
0 trials in Phase 3/4
77%
10 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (122)
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Combination Therapy in Cancers With Mutations in DNA Repair Genes
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers